{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:18:35Z","timestamp":1790360315055,"version":"4.1.0"},"reference-count":66,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Chronic insomnia is common in adults with intellectual disabilities, yet evidence to guide pharmacological management is limited. We report a real-world case series of five adults with intellectual disabilities and multimorbidity treated with daridorexant, a dual orexin receptor antagonist approved in Europe for insomnia. Daridorexant was associated with marked improvements in sleep quality and quantity, despite complex comorbid sleep, physical, mental and neurodevelopmental disorders. Subject to the limitations of a small, uncontrolled case series, these gains were associated with other reported improvements, including a reduction in challenging behaviours, improved daytime functioning and substantial alleviation of parent and carer burden.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-real-world-experience-with-daridorexant-for-insomnia-in-adults-with-intellectual-disabilities-a-retrospective-single-centre-case-series<\/jats:p>","DOI":"10.7573\/dic.2026-5-4","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:56:55Z","timestamp":1782838615000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience with daridorexant for insomnia in adults with intellectual disabilities: a retrospective single-centre case series"],"prefix":"10.7573","volume":"15","author":[{"given":"David","family":"O\u2019Regan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0220mzb33","id-type":"ROR","asserted-by":"publisher"}],"name":"King's College London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref0","unstructured":"1. Korb L, O\u2019Regan D, Conley J, et al. Sleep: the neglected life factor in adults with intellectual disabilities. BJPsych Bull."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2023;47(3):139\u2013145. https:\/\/doi.org\/10.1192\/bjb.2021.122 DOI: 10.1192\/bjb.2021.122","DOI":"10.5858\/arpa.2021-0188-LE"},{"key":"ref2","unstructured":"2. Perera B, O\u2019Regan D. Sleep disorders in adults with intellectual disability: current status and future directions. Curr"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Treat Options Neurol. 2024;26:385\u2013392. https:\/\/doi.org\/10.1007\/s11940-024-00801-x DOI: 10.1007\/s11940-024-00801-x","DOI":"10.1007\/s11940-024-00801-x"},{"key":"ref4","unstructured":"3. Riha RL, Singh A, Hill EA, Evans H, O\u2019Regan D. Sleep-disordered breathing in children and adults with intellectual"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"disability: mind the gap! Thorax. 2024;79(11):1099\u20131107. https:\/\/doi.org\/10.1136\/thorax-2023-220032 DOI: 10.1136\/thorax-2023-220032","DOI":"10.1136\/thorax-2023-220032"},{"key":"ref6","unstructured":"4. Al Lihabi A. A literature review of sleep problems and neurodevelopment disorders. Front Psychiatry."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"2023;14:1122344. https:\/\/doi.org\/10.3389\/fpsyt.2023.1122344 DOI: 10.3389\/fpsyt.2023.1122344","DOI":"10.1039\/D3SC90057F"},{"key":"ref8","unstructured":"5. Lewin G, Kousovista R, Abakasanga E, et al. Nature and prevalence of long-term conditions in people with"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"intellectual disability: retrospective longitudinal population-based study. BMJ Open. 2025;15(1):e090857. DOI: 10.1136\/bmjopen-2024-090857","DOI":"10.1136\/bmjopen-2024-090857"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090857 DOI: 10.1136\/bmjopen-2024-090857","DOI":"10.1136\/bmjopen-2024-090857"},{"key":"ref11","unstructured":"6. NICE. Insomnia. CKS, health topics A to Z. https:\/\/cks.nice.org.uk\/topics\/insomnia\/. Accessed April 15, 2026."},{"key":"ref12","unstructured":"7. Palagini L, Brugnoli R, Dell\u2019 Osso BM, et al. Clinical practice guidelines for switching or deprescribing hypnotic"},{"key":"ref13","unstructured":"medications for chronic insomnia: results of European neuropsychopharmacology and sleep expert\u2019s consensus"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"group. Sleep Med. 2025;128:117\u2013126. https:\/\/doi.org\/10.1016\/j.sleep.2025.01.033 DOI: 10.1016\/j.sleep.2025.01.033","DOI":"10.1016\/j.sleep.2025.01.033"},{"key":"ref15","unstructured":"8. Riemann D, Espie CA, Altena E, et al. The European insomnia guideline: an update on the diagnosis and treatment"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"of insomnia 2023. J Sleep Res. 2023;32(6):e14035. https:\/\/doi.org\/10.1111\/jsr.14035 DOI: 10.1111\/jsr.14035","DOI":"10.1111\/jsr.14035"},{"key":"ref17","unstructured":"9. European Medicines Agency. Daridorexant. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quviviq."},{"key":"ref18","unstructured":"Accessed June 23, 2026."},{"key":"ref19","unstructured":"10. Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"antagonist for the treatment of insomnia. Psychopharmacology. 2021;238(10):2693\u20132708. https:\/\/doi.org\/10.1007\/ DOI: 10.1007\/s00213-021-05954-0","DOI":"10.1007\/s00213-021-05954-0"},{"key":"ref21","unstructured":"s00213-021-05954-0"},{"key":"ref22","unstructured":"11. Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125\u2013139. DOI: 10.1016\/S1474-4422(21)00436-1","DOI":"10.1016\/S1474-4422(21)00436-1"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1. Erratum in: Lancet Neurol. 2022;21(3):e3. https:\/\/doi.org\/10.1016\/ DOI: 10.1016\/S1474-4422(22)00029-1","DOI":"10.1016\/S1474-4422(22)00411-2"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"S1474-4422(22)00029-1. Erratum in: Lancet Neurol. 2022;21(6):e6. https:\/\/doi.org\/10.1016\/S1474-4422(22)00144-2 DOI: 10.1016\/S1474-4422(22)00179-X","DOI":"10.1016\/S1474-4422(22)00411-2"},{"key":"ref26","unstructured":"12. Kunz D, Dauvilliers Y, Benes H, et al. Long-term safety and tolerability of daridorexant in patients with insomnia"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"disorder. CNS Drugs. 2023;37(1):93\u2013106. https:\/\/doi.org\/10.1007\/s40263-022-00980-8 DOI: 10.1007\/s40263-022-00980-8","DOI":"10.1007\/s40263-022-00980-8"},{"key":"ref28","unstructured":"13. Dutta S, Singhal S, Shah R, Charan J, Dhingra S, Haque M. Daridorexant as a novel pharmacotherapeutic approach"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"in insomnia: a systematic review and meta-analysis. Expert Opin Drug Saf. 2023;22(12):1237\u20131251. https:\/\/doi.org\/ DOI: 10.1080\/14740338.2023.2243217","DOI":"10.1080\/14740338.2023.2243217"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"10.1080\/14740338.2023.2243217. Erratum in: Expert Opin Drug Saf. 2024;23(11):1489. https:\/\/doi.org\/10.1080\/ DOI: 10.1080\/14740338.2023.2271793","DOI":"10.1080\/14740338.2023.2271793"},{"key":"ref31","unstructured":"14740338.2023.2271793"},{"key":"ref32","unstructured":"14. Jiang F, Li H, Chen Y, Lu H, Ni J, Chen G. Daridorexant for the treatment of insomnia disorder: a systematic"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"review and meta-analysis of randomized controlled trials. Medicine. 2023;102(7):e32754. https:\/\/doi.org\/10.1097\/ DOI: 10.1097\/MD.0000000000032754","DOI":"10.1097\/MD.0000000000032754"},{"key":"ref34","unstructured":"MD.0000000000032754"},{"key":"ref35","unstructured":"15. Preskorn SH. Comparative pharmacology of the 3 marketed dual orexin antagonists-daridorexant, lemborexant,"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"and suvorexant: part 1: pharmacokinetic profiles. J Psychiatr Pract. 2022;28(6):478-480. https:\/\/doi.org\/10.1097\/ DOI: 10.1097\/PRA.0000000000000672","DOI":"10.1097\/PRA.0000000000000672"},{"key":"ref37","unstructured":"PRA.0000000000000672"},{"key":"ref38","unstructured":"16. Daridorexant for treating long-term insomnia. London: National Institute for Health and Care Excellence (NICE);"},{"key":"ref39","unstructured":"2023 Oct 18. (National Institute for Health and Care Excellence: Technology Appraisals, No. TA922). https:\/\/"},{"key":"ref40","unstructured":"www.ncbi.nlm.nih.gov\/books\/NBK613235\/. Accessed April 15, 2026."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"17. Esbensen AJ, Schwichtenberg AJ. Sleep in neurodevelopmental disorders. Int Rev Res Dev Disabil. 2016;51:153\u2013191. DOI: 10.1016\/bs.irrdd.2016.07.005","DOI":"10.1016\/bs.irrdd.2016.07.005"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/bs.irrdd.2016.07.005 DOI: 10.1016\/bs.irrdd.2016.07.005","DOI":"10.1088\/1475-7516\/2016\/07\/005"},{"key":"ref43","unstructured":"18. National Center for Biotechnology Information (NCBI). MedGen: Ring chromosome 18 (Concept ID: C0265475)."},{"key":"ref44","unstructured":"Bethesda (MD): NCBI; 2024. https:\/\/www.ncbi.nlm.nih.gov\/medgen\/539285. Accessed April 15, 2026."},{"key":"ref45","unstructured":"19. van den Broek N, Broer L, Vandenbussche N, et al. Obstructive sleep apnea in people with intellectual disabilities:"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"adherence to and effect of CPAP. Sleep Breath. 2021;25(3):1257\u20131265. https:\/\/doi.org\/10.1007\/s11325-020-02221-y DOI: 10.1007\/s11325-020-02221-y","DOI":"10.1007\/s11325-020-02221-y"},{"key":"ref47","unstructured":"20. Shayota BJ, Elsea SH. Behavior and sleep disturbance in Smith-Magenis syndrome. Curr Opin Psychiatry."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"2019;32(2):73\u201378. https:\/\/doi.org\/10.1097\/YCO.0000000000000474 DOI: 10.1097\/YCO.0000000000000474","DOI":"10.1097\/YCO.0000000000000474"},{"key":"ref49","unstructured":"21. Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Br J Pharmacol. 2018;175(16):3190\u20133199. https:\/\/doi.org\/10.1111\/bph.14116 DOI: 10.1111\/bph.14116","DOI":"10.1111\/bph.14116"},{"key":"ref51","unstructured":"22. Braam W, Smits MG, Didden R, Korzilius H, Van Geijlswijk IM, Curfs LM. Exogenous melatonin for sleep problems in"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"individuals with intellectual disability: a meta-analysis. Dev Med Child Neurol. 2009;51(5):340\u2013349. https:\/\/doi.org\/10.1111\/ DOI: 10.1111\/j.1469-8749.2008.03244.x","DOI":"10.1111\/j.1469-8749.2008.03244.x"},{"key":"ref53","unstructured":"j.1469-8749.2008.03244.x"},{"key":"ref54","unstructured":"23. Palagini L, Alfi G, Gurrieri R, et al. Early experience with the new DORA daridorexant in patients with insomnia"},{"key":"ref55","unstructured":"disorder and comorbid mental disturbances: results of a naturalistic study with 3 months follow-up. J Sleep Res."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"2024;33(6):e14196. https:\/\/doi.org\/10.1111\/jsr.14196 DOI: 10.1111\/jsr.14196","DOI":"10.1111\/jsr.14196"},{"key":"ref57","unstructured":"24. Briggs AH, Chalet FX, Cooper J, et al. Cost-effectiveness analysis of daridorexant for the pharmacological"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"treatment of chronic insomnia disorder in adults. Pharmacoecon Open. 2025;9(3):379\u2013397. https:\/\/doi.org\/10.1007\/ DOI: 10.1007\/s41669-025-00567-1","DOI":"10.1007\/s41669-025-00567-1"},{"key":"ref59","unstructured":"s41669-025-00567-1"},{"key":"ref60","unstructured":"25. Lettieri CJ, Briasoulis O, L\u00e9ger D, et al. The effects of daridorexant on patients with comorbid insomnia disorder and"},{"key":"ref61","unstructured":"untreated mild obstructive sleep apnoea: a post hoc subgroup analysis of a phase 3, randomised clinical trial. J"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Sleep Res. 2025, 35(2):e70135. https:\/\/doi.org\/10.1111\/jsr.70135 DOI: 10.1111\/jsr.70135","DOI":"10.1111\/jsr.70135"},{"key":"ref63","unstructured":"26. Yeh WC, Li YS, Chang YP, Hsu CY. The efficacy and safety of dual orexin receptor antagonists in obstructive sleep"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"apnea: a systematic review and meta-analysis of randomised controlled trials. J Sleep Res. 2025;34(4):e14399. DOI: 10.1111\/jsr.14399","DOI":"10.1111\/jsr.14399"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jsr.14399 DOI: 10.1111\/jsr.14399","DOI":"10.1111\/jsr.14399"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/07\/dic.2026-5-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:49:41Z","timestamp":1783594181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/real-world-experience-with-daridorexant-for-insomnia-in-adults-with-intellectual-disabilities-a-retrospective-single-centre-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":66,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-5-4","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"2026-5-4"}}